KR20210060121A - composition for improving skin inflammation - Google Patents

composition for improving skin inflammation Download PDF

Info

Publication number
KR20210060121A
KR20210060121A KR1020190147766A KR20190147766A KR20210060121A KR 20210060121 A KR20210060121 A KR 20210060121A KR 1020190147766 A KR1020190147766 A KR 1020190147766A KR 20190147766 A KR20190147766 A KR 20190147766A KR 20210060121 A KR20210060121 A KR 20210060121A
Authority
KR
South Korea
Prior art keywords
cosmetic composition
skin
itching
extract
inflammatory
Prior art date
Application number
KR1020190147766A
Other languages
Korean (ko)
Other versions
KR102300298B1 (en
Inventor
김청택
홍성종
우건식
신상수
전다은
김기수
Original Assignee
주식회사 알엔에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 알엔에스 filed Critical 주식회사 알엔에스
Priority to KR1020190147766A priority Critical patent/KR102300298B1/en
Publication of KR20210060121A publication Critical patent/KR20210060121A/en
Application granted granted Critical
Publication of KR102300298B1 publication Critical patent/KR102300298B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a cosmetic composition having an anti-inflammatory effect and, more specifically, to a cosmetic composition having itching alleviation or anti-inflammatory effects by comprising herbal medicine complex extracts of Centella asiatica, Arctium minus, roots of Anemarrhena asphodeloides, seeds of Nelumbo nucifera, fruits of Forsythia suspensa and flowers of Lonicera japonica as active ingredients. The cosmetic composition having an anti-inflammatory effect according to the present invention is safe for the skin and has excellent anti-inflammatory effect, which is a skin trouble alleviation effect.

Description

피부 염증 개선용 조성물{composition for improving skin inflammation}Composition for improving skin inflammation}

본 발명은 항염 효과를 가지는 화장료 조성물에 관한 것으로서, 보다 상세하게는 피부에 대한 부작용없이 안전하게 사용될 수 있으며 피부 트러블 완화 효과인 항염 효과를 갖는 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition having an anti-inflammatory effect, and more particularly, to a cosmetic composition that can be safely used without side effects on the skin and has an anti-inflammatory effect that is a skin trouble relief effect.

화장품은 피부를 보호하고 피부의 미화 및 청결을 위해 사용되는 제품이지만, 그 조성으로는 피부 보호 목적과는 상이한 성분들이 불가피하게 포함된다. 이러한 성분들로는 계면활성제, 방부제, 향료, 자외선 차단제, 색소뿐만 아니라, 그 밖의 효능 및 효과를 부여하기 위한 여러 가지 성분들이 여기에 포함된다. 이들 성분은 일반적으로 피부에 염증이나 뾰루지, 부종 등 각종 트러블을 발생시키는 것으로 알려져 있다.(Maibach. H. I., Contact Dermatitis, 6. 369-404, 1980) 또한, 체내로부터 배출되는 피지 및 땀, 화장품성분 중 지방산, 고급 알코올, 단백질 성분 등이 피부에 조재하는 피부상재균에 의해 독성이 강한 물질로 분해되어 이들에 의해 피부 염증이 유발될 수도 있으며, 자외선에 의해서도 피부 염증이 유발된다는 것은 잘 알려진 사실이다.Cosmetics are products used to protect the skin and to beautify and clean the skin, but its composition inevitably contains ingredients different from those for skin protection purposes. These ingredients include surfactants, preservatives, fragrances, sunscreens, pigments, as well as various other ingredients to impart efficacy and effects. These ingredients are generally known to cause various problems such as inflammation, rashes, and swelling on the skin. (Maibach. HI, Contact Dermatitis, 6. 369-404, 1980) In addition, sebum and sweat discharged from the body, cosmetic ingredients It is a well-known fact that heavy fatty acids, higher alcohols, proteins, etc., are decomposed into highly toxic substances by dermatophytes that exist on the skin, which may cause skin inflammation, and that even UV rays can cause skin inflammation. .

염증 반응은 붉어짐, 따끔거림, 화끈거림, 팽윤, 조직의 변화와 같은 5가지 현상으로 나타나는데, 이는 해로운 주위 환경, 즉 세균과 같은 외부 물질의 침입과 기계적 손상으로부터 생체를 보호하려는 생리적인 반응이다. 이러한 염증현상은 여러 종류의 다핵형 백혈구(PMNs)와 면역 물질의 많은 증가를 초래하며, 이처럼 증가된 세포들은 염증성 세포 산물인 다양한 종류의 단백질 분해효소와 사이토카인 등을 분비함으로써 치료 및 방어를 할 수 있게 해준다. 그러나, 이러한 작용은 인접해 있는 조직 세포와 비세포 성분들에 해로운 손상을 일으키기도 한다. EK라서, 적절한 조건 하에서는 염증 초기상태가 지난 후 정상 기능을 되찾게 되지만, 염증을 자극하는 자극제가 없어지지 않거나 계속해서 만들어질 경우에는 결과적으로 만성 염증이 일어나게 되어 더욱더 심각한 조직의 손상을 가져온다.The inflammatory response is represented by five phenomena such as redness, tingling, burning, swelling, and tissue change. This is a physiological reaction to protect the living body from the invasion of foreign substances such as bacteria and mechanical damage. This inflammatory phenomenon causes a large increase in various types of polykaryotic leukocytes (PMNs) and immune substances, and these increased cells secrete various types of proteolytic enzymes and cytokines, which are inflammatory cell products, to provide treatment and defense. Allows you to However, this action can also cause detrimental damage to adjacent tissue cells and non-cellular components. As EK, under appropriate conditions, after the initial state of inflammation has passed, normal function is restored, but if the irritant that stimulates the inflammation does not disappear or is made continuously, as a result, chronic inflammation occurs, leading to more serious tissue damage.

염증과 관계되어진 대표적인 피부 트러블의 형태로는 아토피와 여드름 등이 있으며 아토피에 대해서 설명하면 다음과 같다.Representative skin problems related to inflammation include atopy and acne, and atopy is described as follows.

아토피는 심한 가려움증이 특징적인데 피부에 자극을 하면 가려움증이 더욱 심해지고, 자꾸 더 긁다보면 상처가 나게되고, 이로인해 세균감염(황색포도상구균, 연쇄상구균 등)이 일어나게 되어 염증이 일어나게된다. 아토피의 문제 중에 중요한 인자의 하나는 이때 일어나는 2차 감염 및 초항원 독소이다. 이토피 환자의 80~90%는 피부에 황색포도상구균(Staphilococcus aureus)와 연쇄상구균(Stereptococcus pyogenes)의 감염이 있는데, 이때 anti-staphilococcus IgE가 만들어지며, 이에 의해 T-cell반응을 자극하는 초항원 독소에 의해 유발되고 악화시키기도 한다. 황색포도상구균의 초항원 독소는 랑게르한스 세포내 항원제시세포를 통하여 T 임파구를 선택적으로 자극하여 인터루킨-1과 TNF-alpha를 생산하게 하고, 이들에 의해 자극된 T-cell에서 여러 가지 세포내 사이토카인이라는 독소를 분비하여 염증을 일으키게 된다. 즉, 초항원 독소는 인터루킨-4와 인터루틴-5의 분비를 촉진하여 IFN-gamma의 분비는 저해하고, CLA의 수를 증가시켜 결국 IgE의 생성을 촉진시킨다.Atopy is characterized by severe itching.If the skin is irritated, the itching becomes more severe, and if you scratch more and more, the wound will be injured, resulting in bacterial infection (yellow staphylococcus, streptococcus, etc.), resulting in inflammation. One of the important factors in the problem of atopy is the secondary infection and superantigen toxin that occurs at this time. 80-90% of patients with Etopy have infections of Staphilococcus aureus and Streptococcus pyogenes on the skin, where anti-staphilococcus IgE is produced, thereby stimulating the T-cell response. It is also triggered by toxins and exacerbated. Staphylococcus aureus superantigen toxin selectively stimulates T lymphocytes through antigen-presenting cells in Langerhans cells to produce interleukin-1 and TNF-alpha, and various intracellular cytokines in T-cells stimulated by them It secretes a toxin called, causing inflammation. That is, the superantigen toxin promotes the secretion of interleukin-4 and interroutin-5, inhibits the secretion of IFN-gamma, and increases the number of CLA, thereby promoting the production of IgE.

두 번째로는 황색포도상구균에 감염된 환자들이 포도상구균 독소에 대한 IgE 항체에 의하여 호염구에서 히스타민이라는 물질을 분비하게 하고, 이로 인해 아토피 피부염이 악화된다.Second, patients infected with Staphylococcus aureus secrete a substance called histamine from basophils by IgE antibodies against staphylococcal toxins, which worsens atopic dermatitis.

따라서, 피부건조를 막기 위해 보습제의 사용이 자주 권장되는 것이고, 2차 감염 및 이로 인한 초항원 인자의 조절이 매우 중요한 것이다. 즉, 아토피는 유전적 결함을 기본적인 병인으로 보지만, 여러 가지 외부적인 후천적 요소들에 의해 유발을 촉진하게 되는 것이다.Therefore, the use of moisturizers is often recommended to prevent skin dryness, and secondary infection and the control of superantigenic factors resulting therefrom are very important. In other words, atopy sees a genetic defect as a basic etiology, but it is promoted by various external acquired factors.

아토피의 유발 악화인자로는 유전적 요인, 민감하고 건조한 피부, 대사적 요인, IgE의 과도한 생성, 자율신경계의 조절이상, 심리적인 요인, 자극적인 요인 등이 있다.Atopy-induced worsening factors include genetic factors, sensitive and dry skin, metabolic factors, excessive production of IgE, dysregulation of the autonomic nervous system, psychological factors, and stimulating factors.

이렇듯 아토피는 결코 그 기전이 단순하지 않은 질환이다. 면역학적 관점에서도 하나의 면역학적 문제가 아닌 다양한 패턴의 문제점을 가지고 있는 것이다. 한 예로, IgE의 과도한 생성을 억제하는 감마인터페론의 문제도 그 생성이 평균치보다 떨어져서 생기기도 하지만, 반대작용을 하는 인터루킨-4보다 적어서 생기기도 하고, 생성과정이 문제가 있어서 분완전한 인터페론의 생성으로 생기기도 하고 양이나 질적인 면에서 정상이라 하더라도 인터페론의 자극에 민감도가 떨어져 생기는 경우도 발생한다.As such, atopy is a disease whose mechanism is by no means simple. From an immunological point of view, it has a problem of various patterns, not one immunological problem. For example, the problem of gamma interferon, which suppresses excessive production of IgE, occurs because its production is less than the average value, but it is also caused by less than interleukin-4, which acts in the opposite direction, and the production process is problematic, resulting in the production of complete interferon. It may occur, and even if it is normal in terms of quantity or quality, sensitivity to interferon stimulation may decrease.

이러한 다양한 염증 생성 과정의 핵심 물질은 자극에 의해 활성화된 포스포리파아제 A2(Phospholipase A2, PLA2)라는 효소에 의해 세포막 지질로부터 전환된 아라키돈산(arachidonic acid)으로, 아라키돈산은 다시 사이클로옥시게나제(cyclooxygenase, 이하 'COX'로 칭함) 또는 리폭시게나제(lipoxygenase)의 2가지 경로를 거쳐 염증 매개체인 프로스타글란딘류(prostaglandins), 류코트리엔류(leulotrienes)로 대사되어 다양한 염증 반응을 매개한다.(Thomas, R., Rev. Phsiol. Bioche. Pharmacol., 100, 1984)The key substance in these various inflammatory processes is arachidonic acid, which is converted from cell membrane lipids by an enzyme called phospholipase A2 (PLA2) activated by stimulation, and arachidonic acid is again cyclooxygenase. , Hereinafter referred to as'COX') or lipoxygenase, which is metabolized to prostaglandins and leulotrienes, which are inflammatory mediators, through two pathways, mediating various inflammatory reactions (Thomas, R. , Rev. Phsiol. Bioche. Pharmacol., 100, 1984)

최근 피부 자극 및 염증의 생성을 줄일 수 있는 방법에 관한 연구가 활발히 진행되고 있으며, 지금까지의 연구 결과로는 신경세포에서 분비되는 물질 P(substance P) 등의 신경 펩타이드나 자극에 의해 조직이나 혈장에서 활성화되는 브라디키닌과 같은 키닌 등에 의해 또는 COX 경로에 의해 형성된 다양한 사이토카인, 프로스타글란딘 E2(prostaglandin E2, 이하 'PGE2'로 칭함) 등이 부종 형성과 혈관 확장에 관여하여 염증과 통증의 원인이 된다는 것이 알려져 있다. 이에 따라, 항염제로서는 물질 P를 비롯한 신경 펩타이드 길항제, 브라드키닌 길항제, COX 억제제 등이 제시되어 왔으나, 지금까지 알려진 항염제는 피부에 대한 안전성 면에서나, 제품에 포함시킬 때의 안정성 면에서 대부분 문제점을 안고 있어 그 사용이 제한되고 있다.Recently, research on a method to reduce the production of skin irritation and inflammation is actively progressing, and the results of the studies so far have shown that tissues or plasma are stimulated by nerve peptides such as substance P (substance P) secreted from nerve cells. Various cytokines, prostaglandin E2 (prostaglandin E2, hereinafter referred to as'PGE2'), etc., formed by kinins, such as bradykinin activated in, are involved in edema formation and vasodilation, causing inflammation and pain. It is known to be. Accordingly, as anti-inflammatory agents, neuropeptide antagonists, bradykinin antagonists, COX inhibitors, etc., including substance P, have been suggested, but anti-inflammatory agents known so far have most problems in terms of safety for the skin and stability when included in products. So its use is limited.

상기와 같은 문제점을 해결하기 위한 것으로서, 본 발명은 피부에 대한 부작용없이 안전하게 사용될 수 있으며 피부 트러블 완화 효과인 항염 효과를 갖는 화장료 조성물을 제공하는 데 있다. In order to solve the above problems, the present invention is to provide a cosmetic composition that can be safely used without side effects on the skin and has an anti-inflammatory effect, which is an effect of relieving skin troubles.

상기와 같은 기술적 과제를 해결하기 위하여, 본 발명은 병풀, 우방자, 지모뿌리, 연꽃씨, 당개나리열매 및 인동덩굴꽃으로 구성된 복합한약재의 추출물을 유효성분으로 포함하는 것을 특징으로 하는 가려움증 개선 또는 항염 효과를 갖는 화장료 조성물을 제공한다. In order to solve the above technical problem, the present invention improves itching or anti-inflammatory, characterized in that it contains an extract of a complex herbal medicine consisting of centella asiatica, oleander, zymophila root, lotus seed, dandelion berry and honeysuckle flower as an active ingredient. It provides a cosmetic composition having an effect.

본 발명의 화장료 조성물은 피부에 안전하면서도 피부 트러블 완화 효과인 항염 효과가 우수하다. The cosmetic composition of the present invention is safe for the skin and has excellent anti-inflammatory effect, which is a skin trouble relief effect.

이하 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.

본 발명의 항염 효과를 가지는 화장료 조성물은 병풀, 우방자, 지모뿌리, 연꽃씨, 당개나리열매 및 인동덩굴꽃의 혼합물을 온천수로 추출한 한약재 복합추출물을 유효성분으로 포함하는 것을 특징으로 한다. The cosmetic composition having an anti-inflammatory effect of the present invention is characterized in that it comprises as an active ingredient a herbal compound extract obtained by extracting a mixture of centella asiatica, oleifera, limbo root, lotus seed, dandelion berry and honeysuckle flower with hot spring water.

상기 병풀은 병풀(Centella asiatica)의 전초이며, 우방자는 우엉(Arctium lappa)의 씨이며, 지모뿌리는 지모(Anemarrhena asphodeloides)의 뿌리줄기이며, 연꽃씨는 연꽃(Nelumbo nucifera)의 씨이며, 당개나리열매는 당개나리(Forsythia suspensa)의 열매이며, 인동덩굴꽃은 인동덩굴(Lonicera japonica)의 꽃이다.The centella asiatica is an outpost, the ally is the seed of the burdock (Arctium lappa), the root of the celiac is the rootstock of the Anemarrhena asphodeloides, and the lotus seed is the seed of the lotus flower (Nelumbo nucifera), The fruit is the fruit of the Forsythia suspensa, and the honeysuckle flower is the flower of the honeysuckle (Lonicera japonica).

상기 약재는 통상의 방법에 따라 추출물로 제조할 수 있으며, 예를 들어 온천수, 증류수, 탄소수 1~4개의 무수 또는 함수 저급알코올과 같은 유기용매로 추출한 후 여과하는 통상의 방법으로 제조될 수 있다.The medicinal material may be prepared as an extract according to a conventional method, and for example, it may be prepared by a conventional method of extracting with an organic solvent such as hot spring water, distilled water, anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms, and then filtering.

상기 병풀, 우방자, 지모뿌리, 연꽃씨, 당개나리열매 및 인동덩굴꽃의 혼합물을 온천수로 추출한 한약재 복합추출물은 본 발명의 화장료 조성물에 각각 0.0001 내지 20 중량%로 포함되는 것이 바람직하며, 더욱 바람직하게는 0.01 내지 10 중량%로 포함되는 것이다. 그 함량이 0.0001 중량%미만일 경우에는 뚜렷한 효과를 기대할 수 없다. The herbal compound extract obtained by extracting the mixture of centella, wubangja, jimo root, lotus seed, sugar lily fruit and honeysuckle flower with hot spring water is preferably contained in the cosmetic composition of the present invention in an amount of 0.0001 to 20% by weight, and more preferably Is contained in 0.01 to 10% by weight. If the content is less than 0.0001% by weight, a distinct effect cannot be expected.

상기와 같은 본 발명의 병풀, 우방자, 지모뿌리, 연꽃씨, 당개나리열매 및 인동덩굴꽃의 혼합물을 온천수로 추출한 한약재 복합추출물을 유효성분으로 함유하는 항염 효과를 가지는 화장료 조성물의 제형은 특별히 제한되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 구체적으로 상기 화장료 조성물은 유연화장수, 영양화장수, 영양크림, 맛사지크림, 에센스, 팩, 젤, 로션, 연고, 패취 또는 분무제 등의 제형으로 제조할 수 있다.The formulation of a cosmetic composition having an anti-inflammatory effect containing as an active ingredient the herbal compound extract obtained by extracting the mixture of centella asiatica, rhizome, chinensis root, lotus seed, sugar forsythia fruit and honeysuckle flower of the present invention as an active ingredient is not particularly limited. No, it can be appropriately selected according to the purpose. Specifically, the cosmetic composition may be prepared in a formulation such as softening lotion, nutritional lotion, nutritional cream, massage cream, essence, pack, gel, lotion, ointment, patch or spray.

이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.Hereinafter, preferred examples are presented to aid in the understanding of the present invention, but the following examples are only illustrative of the present invention, and the scope of the present invention is not limited to the following examples.

[실시예][Example]

실시예 1 ~ 2Examples 1 to 2

건조된 병풀, 우방자, 지모뿌리, 연꽃씨, 당개나리열매 및 인동덩굴꽃을 동량 혼합한 후 잘게 세절하였다. 세절한 약재 혼합물 100g당 증류수와 온천수 500ml를 가한 후, 상온에서 7일간 숙성시켰다. 그 다음, 상기 추출물들을 순차적으로 0.4 ㎛, 02 ㎛, 0.1 ㎛ 크기의 필터로 여과하여 약재 혼합물의 증류수추출물과 온천수추출물을 각각 제조하였다.After mixing equal amounts of dried Centella asiatica, Rhizoma, Jimo root, lotus seed, Dangali berry, and honeysuckle flower, they were finely chopped. After adding distilled water and 500 ml of hot spring water per 100 g of the minced medicinal mixture, it was aged at room temperature for 7 days. Then, the extracts were sequentially filtered through a filter of 0.4 µm, 02 µm, and 0.1 µm to prepare a distilled water extract and a hot spring water extract of the medicinal mixture.

[실험예][Experimental Example]

실험예 1. NO(nitric oxide) 생성 억제 효과 Experimental Example 1. NO (nitric oxide) production inhibitory effect

상기 실시예 1 내지 2에서 제조한 약재 혼합물 추출물의 항염 효과의 피부트러블 완화 기능을 확인하기 위하여 NO 생성 억제 효과 시험을 실시하였다. In order to confirm the skin trouble alleviation function of the anti-inflammatory effect of the herbal mixture extract prepared in Examples 1 to 2, a NO generation inhibitory effect test was performed.

대식세포 계열인 RAW 264.7 세포를 10% FBS가 첨가된 DMEM 배지를 사용하여 24-웰 플레이트에 2 X 105 cell/ml로 분주하고, LPS(500ng/ml)를 처리하고 1시간 후 추출물 시료를 농도별로 처리하여 24시간 배양하였다. 생성된 NO는 Griess시약을 사용하여 세포배양액에 녹아있는 NO2 -의 형태로 측정하였다. 세포배양액 100ul와 Griess시약 100ul를 혼합하여 96 웰플레이트에서 20분간 반응시킨 후 540nm에서 흡광도를 측정하여 정량함으로써 시료의 NO 생성 억제 효과를 판단하고 그 결과를 하기 표 1에 나타내었다. Macrophage RAW 264.7 cells were dispensed into a 24-well plate at 2 X 10 5 cells/ml using DMEM medium supplemented with 10% FBS, treated with LPS (500 ng/ml), and an extract sample was prepared after 1 hour. Treated by concentration and cultured for 24 hours. The generated NO was measured in the form of NO 2 - dissolved in the cell culture solution using the Griess reagent. 100ul of cell culture solution and 100ul of Griess reagent were mixed and reacted in a 96-well plate for 20 minutes, and the absorbance was measured and quantified at 540nm to determine the NO production inhibitory effect of the sample, and the results are shown in Table 1 below.

시료sample 억제율(%)Inhibition rate (%) 대조군Control -- 실시예 1
(증류수 추출물)
Example 1
(Distilled water extract)
100ppm 100ppm 2323
200ppm 200ppm 3232 1000ppm 1000ppm 5757 2000ppm 2000ppm 7575 실시예 2
(온천수 추출물)
Example 2
(Hot spring water extract)
100ppm 100ppm 3131
200ppm 200ppm 3737 1000ppm 1000ppm 6969 2000ppm 2000ppm 8787

상기 표 1에서 보는 바와 같이, 본 발명의 실시예 1 내지 2는 매우 강력한 NO 생성 억제 효과를 나타내었으며, 증류수를 이용한 추출물에 비하여 온천수를 이용한 추출물의 효능이 더욱 우수함을 알 수 있었다.As shown in Table 1, Examples 1 to 2 of the present invention generate very strong NO It showed an inhibitory effect, and it was found that the efficacy of the extract using hot spring water was more excellent than that of the extract using distilled water.

[제조예][Production Example]

제조예 1 및 비교예 1Preparation Example 1 and Comparative Example 1

상기 실시예 2를 이용하여 하기 표 2의 처방으로 피부 외용 연고를 제조하였다. Using Example 2, an ointment for external use of the skin was prepared according to the formulation shown in Table 2 below.

조성물Composition 중량%weight% 제조예 1Manufacturing Example 1 비교예1Comparative Example 1 실시예 2의 추출물
디에틸 세바케이트
경납
폴리옥시에틸렌올레일에테르포스페이트
벤조산 나트륨
바셀린
Extract of Example 2
Diethyl sebacate
Abiding
Polyoxyethylene oleyl ether phosphate
Sodium benzoate
vaseline
2
8
5
6
적량
To 100
2
8
5
6
Appropriate amount
To 100
-
8
5
6
적량
To 100
-
8
5
6
Appropriate amount
To 100

제조예 2 및 비교예 2Preparation Example 2 and Comparative Example 2

상기 실시예 2을 이용하여 하기 표 3의 처방으로 크림을 제조하였다. Using Example 2, a cream was prepared according to the formulation shown in Table 3 below.

조성물Composition 중량%weight% 제조예 2Manufacturing Example 2 비교예 2Comparative Example 2 실시예 2의 추출물
스테아린산
세탄올
수산화칼륨
글리세린
프로필렌글리콜
방부제

정제수
Extract of Example 2
Stearic acid
Cetanol
Potassium hydroxide
glycerin
Propylene glycol
antiseptic
incense
Purified water
2
15
1
0.7
5
3
적량
적량
To 100
2
15
One
0.7
5
3
Appropriate amount
Appropriate amount
To 100
-
15
1
0.7
5
3
적량
적량
To 100
-
15
One
0.7
5
3
Appropriate amount
Appropriate amount
To 100

제조예 3 및 비교예 3Preparation Example 3 and Comparative Example 3

상기 실시예 2을 이용하여 하기 표 4의 처방으로 유연화장수를 제조하였다. Using Example 2, a flexible lotion was prepared according to the formulation shown in Table 4 below.

조성물Composition 중량%weight% 제조예 3Manufacturing Example 3 비교예 3Comparative Example 3 실시예 2의 추출물
에탄올
폴리라우린산폴리옥시에틸렌소르비탄
파라옥시안식향산메틸
글리세린
13-부틸렌글리콜

색소
정제수
Extract of Example 2
ethanol
Polylaurate polyoxyethylene sorbitan
Methyl paraoxybenzoate
glycerin
13-butylene glycol
incense
Pigment
Purified water
2
10
1
0.2
5
6
적량
적량
To 100
2
10
One
0.2
5
6
Appropriate amount
Appropriate amount
To 100
-
10
1
0.2
5
6
적량
적량
To 100
-
10
One
0.2
5
6
Appropriate amount
Appropriate amount
To 100

제조예 4 및 비교예 4Preparation Example 4 and Comparative Example 4

상기 실시예 2을 이용하여 하기 표 5의 처방으로 영양화장수를 제조하였다. Using Example 2, nutrient cosmetic water was prepared according to the formulation shown in Table 5 below.

조성물Composition 중량%weight% 제조예 4Manufacturing Example 4 비교예 4Comparative Example 4 실시예 2의 추출물
바셀린
세스퀴올레인산소르비탄
폴리옥시에틸렌올레일에틸
파라옥시안식향산메틸
프로필렌글리콜
에탄올
카르복시비닐폴리머
수산화칼륨
색소

정제수
Extract of Example 2
vaseline
Sorbitan sesquioleate
Polyoxyethyleneoleylethyl
Methyl paraoxybenzoate
Propylene glycol
ethanol
Carboxyvinyl polymer
Potassium hydroxide
Pigment
incense
Purified water
2
2
1
1
적량
5
3
18
0.1
적량
적량
To 100
2
2
One
One
Appropriate amount
5
3
18
0.1
Appropriate amount
Appropriate amount
To 100
-
2
1
1
적량
5
3
18
0.1
적량
적량
To 100
-
2
One
One
Appropriate amount
5
3
18
0.1
Appropriate amount
Appropriate amount
To 100

[실험예][Experimental Example]

실험예 2. 가려움증 및 아토피 피부염 개선 효과 실험Experimental Example 2. Itching and atopic dermatitis improvement effect experiment

아토피 피부염으로 진단된 환자 중 심한 가려움증을 호소하는 20여명을 선정하여 제조예 2 및 비교예 2에 따라 제조된 화장료를 양팔의 환부에 1일 2회씩(4주)도포하였다. 제조예와 비교예의 가려움증 정도 및 아토피 피부염의 정도를 문진 및 육안으로 판정하고, 제조예가 비교예에 비해 가려움증 및 아토피 피부염 개선 정도를 뚜렷한 효과, 효과 있음, 차이 없음의 3단계로 평가하였으며, 그 결과를 하기 표 10에 나타내었다.Among the patients diagnosed with atopic dermatitis, about 20 patients complaining of severe itching were selected, and the cosmetics prepared according to Preparation Example 2 and Comparative Example 2 were applied twice a day (4 weeks) to the affected areas of both arms. The degree of itching and the degree of atopic dermatitis in Preparation Example and Comparative Example were judged by examination and visual inspection, and the degree of improvement in itching and atopic dermatitis in Preparation Example compared to Comparative Example was evaluated in three stages of distinct effect, effect, and no difference, and the result It is shown in Table 10 below.

시험항목Test Items 뚜렷한 효과(명)Distinct effect (persons) 효과있음(명)Effective (persons) 차이 없음(명)No difference (persons) 가려움증 개선Itching improvement 99 1111 00 아토피 피부염 개선Atopic dermatitis improvement 44 1515 22

상기 표 6의 결과에서 볼 수 있듯이, 제조예 2에 따라 제조된 화장료는 피 시험자 20명 중에서 가려움증 및 아토피 피부염 개선 효과가 매우 우수하였으며, 피부 내에서 어떤 부작용도 나타나지 않아, 안전하고 효과가 매우 뛰어난 가려움증 및 아토피 피부염 개선용 화장료임을 알 수 있다.As can be seen from the results of Table 6, the cosmetic prepared according to Preparation Example 2 was very excellent in improving itchiness and atopic dermatitis among 20 test subjects, and did not show any side effects in the skin, and was safe and very effective. It can be seen that it is a cosmetic for improving itchiness and atopic dermatitis.

Claims (5)

병풀, 우방자, 지모뿌리, 연꽃씨, 당개나리열매 및 인동덩굴꽃으로 구성된 복합한약재의 추출물을 유효성분으로 포함하는 것을 특징으로 하는 가려움증 개선 또는 항염 효과를 갖는 화장료 조성물A cosmetic composition having an itching improvement or anti-inflammatory effect, characterized in that it contains as an active ingredient an extract of a complex herbal medicine consisting of Centella asiatica, oleifera, chinensis root, lotus seed, sugar lily fruit and honeysuckle 제 1항에 있어서,
병풀 : 우방자 : 지모뿌리 : 연꽃씨 : 당개나리열매 : 인동덩굴꽃의 중량비는 1 : 0.1 ∼ 10 : 0.1 ∼ 10 : 0.1 ∼ 10인 것을 특징으로 하는 화장료 조성물
The method of claim 1,
Centella asiatica: zymophila: roots: lotus seed: sugar lily fruit: honeysuckle flower, the weight ratio of 1: 0.1 ∼ 10: 0.1 ∼ 10: 0.1 ∼ 10
제 1항 또는 제 2항에 있어서,
상기 가려움증은 두피 가려움증 또는 아토피 피부염인 것을 특징으로 하는 화장료 조성물
The method according to claim 1 or 2,
Cosmetic composition, characterized in that the itching is scalp itching or atopic dermatitis
제 1항 또는 제 2항에 있어서,
상기 추출물은 정제수, 온천수, C1 내지 C4의 저급 알코올 또는 이들의 혼합물로 이루어진 군에서 선택된 용매로 추출한 것을 특징으로 하는 화장료 조성물
The method according to claim 1 or 2,
The extract is a cosmetic composition, characterized in that it is extracted with a solvent selected from the group consisting of purified water, hot spring water, C1 to C4 lower alcohol, or a mixture thereof
제 1항에 있어서, 상기 유효성분의 함량은 조성물 총 중량을 기준으로 0.00001 내지 20 중량%인 것을 특징으로하는 항염 효과를 가지는 화장료 조성물.The cosmetic composition of claim 1, wherein the content of the active ingredient is 0.00001 to 20% by weight based on the total weight of the composition.
KR1020190147766A 2019-11-18 2019-11-18 composition for improving skin inflammation KR102300298B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020190147766A KR102300298B1 (en) 2019-11-18 2019-11-18 composition for improving skin inflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190147766A KR102300298B1 (en) 2019-11-18 2019-11-18 composition for improving skin inflammation

Publications (2)

Publication Number Publication Date
KR20210060121A true KR20210060121A (en) 2021-05-26
KR102300298B1 KR102300298B1 (en) 2021-09-09

Family

ID=76137622

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190147766A KR102300298B1 (en) 2019-11-18 2019-11-18 composition for improving skin inflammation

Country Status (1)

Country Link
KR (1) KR102300298B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4137143A1 (en) * 2021-08-17 2023-02-22 All In On Co., Ltd Composition for anti-oxidation and anti-inflammation comprising salvia plebeia r br extract and centella asiatica extract
KR102534797B1 (en) 2022-10-24 2023-05-30 주식회사 에이바이오머티리얼즈 Preparation method of nanoparticles containing anemarrhena asphodeloides extract, polydeoxyribonucleotide and physiologically active materials and cosmetic composition comprising the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200064229A (en) * 2018-11-28 2020-06-08 김범수 Composition for antiinflammation containing natural complex extracts as active ingredient

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200064229A (en) * 2018-11-28 2020-06-08 김범수 Composition for antiinflammation containing natural complex extracts as active ingredient

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4137143A1 (en) * 2021-08-17 2023-02-22 All In On Co., Ltd Composition for anti-oxidation and anti-inflammation comprising salvia plebeia r br extract and centella asiatica extract
KR102534797B1 (en) 2022-10-24 2023-05-30 주식회사 에이바이오머티리얼즈 Preparation method of nanoparticles containing anemarrhena asphodeloides extract, polydeoxyribonucleotide and physiologically active materials and cosmetic composition comprising the same

Also Published As

Publication number Publication date
KR102300298B1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
KR20110083817A (en) Cosmetic composition for improving dermatitis
KR102147833B1 (en) A cosmetic composition for improving skin containing a peptide
KR20180014356A (en) Composition for alleviating skin irritation and skin inflammation induced by particulate matter comprising extracts mixture of Ocimum sanctum, Mentha haplocalyx, and Azadirachta indica
KR102300298B1 (en) composition for improving skin inflammation
KR101917645B1 (en) Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract
KR101332215B1 (en) Cosmetic composition containing fermentated complex of extracts with cryptomeria japonica and nelumbo nucifera for acne improvement and enhancing immune system
KR100668290B1 (en) Cosmeceutical compositions comprising a Rumex acetosella L. extract and/or a Rheum coreanum extract with improvement effect of atopic dermatitis
KR20110068258A (en) Composition for anti-inflammation
KR101383519B1 (en) Composition having excellent antibacterial effect and manufacturing method thereof and cosmetic composition comprising thereof
DE102015102020A9 (en) Immunologically active phytogen mixture and its use in prevention and in a process for the treatment of efflorescences
KR20150112103A (en) Compositions for improving skin conditions comprising plant extracts or fractions thereof
KR101231864B1 (en) Cosmetic composition for improving skin inflammation using deep ocean water
KR102400090B1 (en) Cosmetic Composition for Reducing Skin Wrinkle
KR20190012818A (en) Composition for External Use Comprising Chionanthus Retusus Extracts for Alleviating Skin Irritation or Skin Inflammation
KR20180124443A (en) Cosmetic composition for enhancing skin barrier containing extract of Tremella fuciformis fruiting body
KR102616141B1 (en) Vegan cosmetic composition containing eight complex to improve skin inflammation and skin itchiness
KR102059620B1 (en) Cosmetic composition for allevation of acne with the extract of Lycopus lucidus or its fraction
KR20210061548A (en) flavanone derivative composition for improving skin inflammation
KR20090085844A (en) Cosmetic composition containing natural medicinal plant extract for alleviating skin inflammation
KR102630567B1 (en) Liposome composition and manufacturing method thereof that have an effect of improving skin absorption rate depending on the eight complex-containing substances
KR100946584B1 (en) Cosmetic Composition Comprising Poncirus trifoliata fruit extract and Nymphaea caerulea extract
KR102561081B1 (en) Cosmetic Composition having antioxidant, antibacterial, skin moisturing and anti-inflammatory Effect
KR102097834B1 (en) Composition for improving atopic skin comprising 7, 8, 4'-trihydroxyisoflavone as active ingredient
KR102416652B1 (en) Cosmetic composition for anti-irritation due to the particulate matter and improving skin conditions
KR102103771B1 (en) Skin externa composition for impriving inflammation containing extract of garcomoa cambogia

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right